Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onartuzumab and/or Bevacizumab with Paclitaxel in TNBC
NCT01186991Phase 2Completed
- Sponsor
- Genentech
- Start
- Mar 2011
- Primary completion
- Mar 2016
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of onartuzumab in triple-negative breast cancer (TNBC), sponsored by Genentech. Started Mar 2011; status: completed.
02
Drugs
onartuzumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT01186991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01186991.